Arrhythmias & electrophysiology
Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study
Study context
- Population
- Atrial fibrillation (AF) patients who have received the Cox-Maze IV (CMIV) procedure, with and without T2DM or heart failure (HF)planned enrolment
- Participants
- 240 patients
- Planned comparison
- Dapagliflozin vs placebo after Cox-Maze IV
- Dapagliflozinn = 120
- Placebon = 120reference
- Primary endpoint
- Any documented atrial tachyarrhythmia (AF, atrial flutter or atrial tachycardia) lasting 30 s
- Follow-up
- Following a blanking period of 3 months after CMIV
Methodological detailsrationale and design paper, prospective, double-blind, placebo-controlled
- Rationale and design paper
- Prospective
- Double-blind
- Placebo-controlled
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study. Europace. Published 6 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →